News | Stem Cell Therapies | February 01, 2019

Heart Muscle Cells Created From Stem Cells Beat in Sync

New study shows how newly created cardiac muscle cells can be made to pump together

Heart Muscle Cells Created From Stem Cells Beat in Sync

February 1, 2019 — A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a new model that would reduce the need for bypass surgery, heart transplants or artificial pumping devices.

The study, recently published in Frontiers in Cell and Developmental Biology,1 involved removing connective tissue cells from a human heart, reverse-engineering them into heart stem cells, then re-engineering them into heart muscle cells.

The Rutgers team’s true breakthrough, however, is that the newly created cardiac muscle cells clumped together into a single unit that visibly pumps under the microscope.

Senior author Leonard Y. Lee, chair of the Department of Surgery at Rutgers Robert Wood Johnson Medical School, said cardiac cells made in this way do not normally come together and beat as one. His team succeeded in making this happen by over-expressing, a protein in the cells called CREG.

According to Lee, fibroblasts, a cell in connective tissue, were isolated from the heart tissue and reverse-engineered – or transformed – into stem cells.  This was done so that when the CREG protein was over-expressed the stem cells would differentiate into cardiac cells.

Heart failure has reached epidemic proportions. Right now, the only option to treat it is surgery, transplant or connecting the patient with a blood-pumping machine,” Lee said. “But transplantable hearts are in short supply and mechanical devices limit the patient’s quality of life. So, we are working for ways to help hearts heal themselves.”

Though still far off, Lee’s ultimate goal is to be able to remove small amounts of a patient’s native heart tissue, use CREG to convert the tissue into cardiac muscles that will work together cohesively, and re-introduce them into the patient’s heart allowing it to heal itself.

For more information: www.frontiersin.org/journals/cell-and-developmental-biology

Reference

1. Ghobrial G., Araujo L., Jinwala F., et al. The Structure and Biological Function of CREG. Frontiers in Cell and Developmental Biology, Oct. 26, 2018. https://doi.org/10.3389/fcell.2018.00136

Related Content

Sponsored Content | Videos | Heart Failure | February 13, 2019
William O'Neill, M.D., highlights best practice protocols based on Impella Quality database and real-world evidence s
EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Overlay Init